

Changes in Prostaglandin E₂ Levels in Seminal Plasma during Ejaculation and the Effect of Exogenous Prostaglandin E₂ on Semen Volume in the Dog

Masanori KOBAYASHI^{1)*}, Tatsuya HORI¹⁾ and Eiichi KAWAKAMI¹⁾

¹⁾Laboratory of Reproduction, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan

(Received 31 January 2013/Accepted 16 April 2013/Published online in J-STAGE 30 April 2013)

ABSTRACT. In healthy male dogs, peripheral plasma testosterone (T), prostaglandin E₂ (PGE₂) and seminal plasma PGE₂ levels were measured before, during and after ejaculation, and semen quality was examined after oral administration of PGE₂. Plasma T and PGE₂ levels did not change during these periods, but the seminal plasma PGE₂ level of combined the first and second fractions was significantly higher than those at 0–5 and 5–10 min after the start of ejaculation of the third fraction. Semen volume but not quality increased after PGE₂ administration. In conclusion, large amounts of PGE₂ are released from the prostate gland during the early part of ejaculation, and PGE₂ plays an essential role in secretion of seminal plasma.

KEY WORDS: canine, ejaculation, prostaglandin E₂, seminal plasma.

doi: 10.1292/jvms.13-0053; *J. Vet. Med. Sci.* 75(9): 1249–1252, 2013

Prostaglandins (PGs) are eicosanoid hormones. Many different PGs are contained within ejaculated semen [18, 19] and are mainly synthesized in the accessory reproductive glands, such as the seminal vesicles and prostate gland [2]. It was previously shown that prostaglandin F_{2α} (PGF_{2α}) administration increased the total number of sperm or sperm concentration in many mammals including rabbits and bulls [6, 14], but did not change the number of spermatozoa in dogs [20]. On the other hand, prostaglandin E₂ (PGE₂) administration in rabbits led to an increase in sperm concentration [14]. While PGF_{2α} supplementation suppressed sperm motility and induced sperm membrane damage and permeability in bulls [5], it was shown that PGE₂ could improve the motility of spermatozoa in men [4]. Moreover, PGE induced both Ca²⁺ influx through the PGE receptor and the acrosome reaction in human spermatozoa [16]. However, to our knowledge, the kinetics and function of PGE₂ during ejaculation in dogs remain unclear.

The primary purpose of this study was to evaluate the association between seminal emission and PGE₂ secretion by measurement of PGE₂ in peripheral blood and seminal plasma in dogs. Moreover, semen quality was examined for investigation of PGE₂ function by PGE₂ administration.

After a set of indwelling needles was inserted into the cephalic vein of 5 male dogs (2–4 years old) with normal semen quality, blood samples were collected 10 and 5 min before ejaculation; immediately before ejaculation; 5, 10 and 15 min after the start of ejaculation; and 0, 5 and 10 min after the end of ejaculation. The semen was collected by digital manipulation. The blood samples were used to mea-

sure testosterone (T) and PGE₂ levels. All T measurements were obtained with an enzyme-linked fluorescence assay kit (VIDAS testosterone, SYSMEX bioMerieux, Tokyo, Japan) using an automated fluorescence immunochemistry analyzer (SPOTCHEM VIDAS SV-5010; ARKRAY, Kyoto, Japan). PGE₂ concentration was measured using a prostaglandin E metabolite enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI, U.S.A.) and a fluorescence microplate reader (Powerscan HT; DS Pharma Biomedical, Osaka, Japan). The amount of PGE₂ in seminal plasma was calculated by the following formula: PGE₂ concentration (pg/ml) in each fraction × seminal plasma volume (ml) of each fraction. This value was expressed as the mean ± standard error (SE). Time course changes in plasma T and PGE₂ levels were evaluated using a one-way analysis of variance (one-way ANOVA) to determine differences among the groups. When a significant difference was found in one-way ANOVA, intergroup comparisons were undertaken using Tukey-Kramer's post hoc test and were considered statistically significant at *P* values less than 0.05.

Semen samples collected from the dogs were separated into the combined first and second fraction and the third fraction, which was ejaculated following the second fraction [7, 9]. To obtain separate fractions of ejaculated semen, the collection tubes were changed after collecting the end of the second fraction. In addition, the third fraction was collected every 5 min, separated and stored. PGE₂ levels were measured in seminal plasma samples extracted by centrifugation.

Furthermore, 4 of 5 male dogs used in the above experiment were given oral PGE₂ 0.1 mg/kg (Dinoprostone; Kaken Pharmaceutical Co., Ltd., Tokyo, Japan), and semen collection was performed 1 hr after administration. Semen qualities including volume of each semen fraction and sperm number, motility, viability and abnormality were analyzed, and the effect of PGE₂ on ejaculation was examined by comparison of these variables between samples from dogs before PGE₂ administration (average values obtained from

*CORRESPONDENCE TO: KOBAYASHI, M., Laboratory of Reproduction, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan.
e-mail: m-koba@nvlu.ac.jp




Fig. 1. (A) Time course changes in prostaglandin E₂ level (black line, mean \pm standard error (SE), pg/ml) and testosterone level (gray line, mean \pm standard error (SE), ng/ml) before and after the start of ejaculation in plasma of 5 normal dogs (n=5). (B) Time course changes in PGE₂ levels (mean \pm SE, pg) in seminal plasma of these dogs. Ejaculated semen was divided into the combined first and second fractions (1F/2F) and 0–5, 5–10, 10–15 and 15–20 min after the start of ejaculation of the third fraction (3F) ejaculated following the second fraction, and PGE₂ levels were measured (n=5). *N.S.*, not significant. **P*<0.05; ***P*<0.01, for a 2-group comparison.

5 examinations of semen properties within 5 months, n=4) and samples from dogs after PGE₂ administration (the same dogs, n=4). In addition, blood was collected before and 1 hr after PGE₂ administration to confirm an increase in PGE₂ level. These variables were evaluated using a paired *t*-test and were considered statistically significant at *P* values less than 0.05.

Time course measurement of PGE₂ and T levels showed no significant differences in the levels of these hormones before and after ejaculation (Fig. 1A). However, the PGE₂

level of the combined first and second fractions of semen (27.1 ± 5.9 pg) was significantly increased in comparison with those of the third fraction collected 0–5 (11.4 ± 2.0 pg, *P*<0.05) and 5–10 min (2.9 ± 0.9 pg, *P*<0.01) after the start of ejaculation of the third fraction (ANOVA, *F*=9.67, *P*<0.01). The PGE₂ level of the third fraction collected 0–5 min after the start of ejaculation of the third fraction tended to increase compared with that collected 5–10 min after the start of ejaculation of the third fraction, but the difference was not statistically significant (Fig. 1B).

Table 1. Plasma PGE₂ concentration (mean ± SE, pg/ml) just before (Pre-PGE₂) and 1 hr after (Post-PGE₂) oral administration of 0.1 mg/kg PGE₂ (n=4)

	Pre-PGE ₂	Post-PGE ₂
PGE ₂ concentration (pg/ml)	96.8 ± 24.3	2,618.7 ± 740.3*

**P*<0.05 for a 2–group comparison.

In the blood collected before and after oral administration of PGE₂ and semen collected after PGE₂ administration in the 4 dogs, the serum PGE₂ level 1 hr after PGE₂ administration (2,618.7 ± 740.3 pg/ml) was markedly increased in comparison with that before administration (96.8 ± 24.3 pg/ml, *P*<0.05) (Table 1). Moreover, the volume of the third fraction (7.8 ± 1.8 ml) and total semen volume (10.3 ± 2.5 ml) after PGE₂ administration were significantly increased compared with before administration of PGE₂ (5.6 ± 1.6 ml, *P*<0.05 and 8.0 ± 2.2 ml, *P*<0.05, respectively), but the volume of the combined first and second fractions showed no significant change between before (2.4 ± 0.6 ml) and after administration of PGE₂ (2.5 ± 0.8 ml). In addition, comparison of total number of sperm, sperm motility, viability and abnormality showed no significant differences between before (5.8 ± 1.1 × 10⁸, 79.5 ± 6.6%, 88.6 ± 3.1% and 8.3 ± 2.0%, respectively) and after PGE₂ administration (8.1 ± 2.0 × 10⁸, 86.3 ± 2.4%, 95.0 ± 1.3% and 5.1 ± 1.6%, respectively) (Table 2).

PGs, such as PGE and PGF₂α, are primarily produced in the accessory glands of the reproductive tract and have been shown to affect motility [1, 3, 4, 17], acrosome reaction [15, 16], capacitation, and fertilizing ability of sperm [8, 15]. The present results revealed that PGE₂ production was dramatically increased not in serum but in seminal plasma immediately following ejaculation in male dogs. Previous studies showed no changes in plasma PGE₂ levels in prostatectomized dogs treated with T, but a rise in plasma levels in intact treated dogs [10]. Therefore, PGE₂ is immediately produced and secreted in the prostate gland during the early part of ejaculation.

In addition, PGE₂ administration was found to lead to an increase in the volume of seminal plasma compared with the untreated control. PGE₂ binds to a family of specific E-prostanoid (EP) receptors, including EP1, EP2, EP3 and EP4 receptors. In particular, the action of PGE₂ on EP2 and EP4 receptors was found to stimulate adenylate cyclase and cause relaxation of vascular smooth muscles, leading to the dilatation of blood vessels [12, 13]. Moreover, excitatory activity of EP1 and EP3 receptors produced smooth muscle contraction, which was mediated by Ca²⁺ mobilization or inhibition of adenylate cyclase [13]. In another study, it was shown that EP receptors, such as EP2 and EP3, were expressed in non-tumorigenic gland cells of human prostate tissue [11]. The present results together with previous findings indicate the possibility that production and secretion of a large quantity of seminal plasma in response to PGE₂ administration are associated with the direct effects of prostatic epithelial cells,

Table 2. Comparison (mean ± SE) of the combined first and second fraction (1F/2F) and third fraction volumes (3F), total semen volume, total number of sperm, sperm motility, sperm viability and sperm abnormality between untreated control (non-PGE₂) and PGE₂-treated dogs (PGE₂) (n=4)

	Non-PGE ₂	PGE ₂
1F/2F volume (ml)	2.4 ± 0.6	2.5 ± 0.8
3F volume (ml)	5.6 ± 1.6	7.8 ± 1.8*
Total semen volume (ml)	8.0 ± 2.2	10.3 ± 2.5*
Total number of sperm (×10 ⁸)	5.8 ± 1.6	8.3 ± 2.0
Sperm motility (%)	79.5 ± 6.6	86.3 ± 2.4
Sperm viability (%)	88.6 ± 3.1	95.0 ± 1.3
Sperm abnormality (%)	8.3 ± 2.0	5.1 ± 1.6

N.S.: Not significant. **P*<0.05 for a 2–group comparison.

smooth muscle contraction around the prostate gland and/or vasodilating action. In addition, no significant change in semen quality, including sperm motility, was found in the present study in response to PGE₂ administration. Sperm velocity increases after incubation for 3 hr in the presence of PGE₂ [1], so the reason why semen motility did not improve following PGE₂ administration might include the time of exposure of sperm to PGE₂.

It is concluded that production and secretion of PGE₂ in the prostate gland increase immediately at the start of ejaculation and that PGE₂ plays an essential role in the ejection of a large quantity of seminal plasma in male dogs.

REFERENCES

- Aitken, R. J. and Kelly, R. W. 1985. Analysis of the direct effects of prostaglandins on human sperm function. *J. Reprod. Fertil.* **73**: 139–146. [Medline] [CrossRef]
- Bendvold, E., Gottlieb, C., Svanborg, K., Gilljam, H., Strandvik, B., Bygdeman, M. and Eneroth, P. 1986. Absence of prostaglandins in semen of men with cystic fibrosis is an indication of the contribution of the seminal vesicles. *J. Reprod. Fertil.* **78**: 311–314. [Medline] [CrossRef]
- Cohen, M. S., Colin, M. J., Golimbu, M. and Hotchkiss, R. S. 1977. The effects of prostaglandins on sperm motility. *Fertil. Steril.* **28**: 78–85. [Medline]
- Colon, J. M., Ginsburg, F., Lessing, J. B., Schoenfeld, C., Goldsmith, L. T., Amelar, R. D., Dubin, L. and Weiss, G. 1986. The effect of relaxin and prostaglandin E2 on the motility of human spermatozoa. *Fertil. Steril.* **46**: 1133–1139. [Medline]
- Fayed, A. H. 1996. Effect of prostaglandin F2 alpha and methylxanthines on enzymic release of bull epididymal spermatozoa *in vitro*. *Contraception* **53**: 181–184. [Medline] [CrossRef]
- Hafs, H. D., Louis, T. M., Waters, R. J., Stellflug, J. N. and Haynes, N. B. 1974. Increased sperm output of rabbits and bulls treated with prostaglandin F2 alpha. *Prostaglandins* **8**: 417–422. [Medline]
- Harrop, A. E. 1960. *Reproduction in the dog*. p. 72. Bailliere, Tindall & Cox, London.
- Herrero, M. B., Viggiano, J. M., Boquet, M. and Gimeno, M. A. 1997. Prostaglandin modulation of mouse and human sperm capacitation. *Prostaglandins Leukot. Essent. Fatty Acids* **57**: 279–284. [Medline] [CrossRef]

9. Kawakami, E., Tsutsui, T., Yamada, Y. and Yamauchi, M. 1984. Cryptorchidism in the dog: occurrence of cryptorchidism and semen quality in the cryptorchid dog. *Jpn. J. Vet. Sci.* **46**: 303–308. [[Medline](#)] [[CrossRef](#)]
10. Klein, L. A., Stoff, J. S. and Ellis, J. 1982. Acute effects of testosterone on serum PGE2 levels in male dogs. *Prostaglandins* **24**: 467–473. [[Medline](#)]
11. Miyata, Y., Kanda, S., Maruta, S., Matsuo, T., Sakai, H., Hayashi, T. and Kanetake, H. 2006. Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. *Urology* **68**: 1360–1365. [[Medline](#)] [[CrossRef](#)]
12. Narumiya, S., Sugimoto, Y. and Ushikubi, F. 1999. Prostanoid receptors: structures, properties, and functions. *Physiol. Rev.* **79**: 1193–1226. [[Medline](#)]
13. Negishi, M., Sugimoto, Y. and Ichikawa, A. 1995. Molecular mechanisms of diverse actions of prostanoid receptors. *Biochim. Biophys. Acta* **1259**: 109–119. [[Medline](#)] [[CrossRef](#)]
14. Reichard, L. A., Hafs, H. D., Haynes, N. B., Collier, R. J., Kiser, T. E. and McCarthy, M. S. 1978. Sperm output and serum testosterone in rabbits given prostaglandin F2alpha or E2. *Prostaglandins* **16**: 135–142. [[Medline](#)]
15. Roy, A. C. and Ratnam, S. S. 1992. Biosynthesis of prostaglandins by human spermatozoa *in vitro* and their role in acrosome reaction and fertilization. *Mol. Reprod. Dev.* **33**: 303–306. [[Medline](#)] [[CrossRef](#)]
16. Schaefer, M., Hofmann, T., Schultz, G. and Gudermann, T. 1998. A new prostaglandin E receptor mediates calcium influx and acrosome reaction in human spermatozoa. *Proc. Natl. Acad. Sci. U. S. A.* **95**: 3008–3013. [[Medline](#)] [[CrossRef](#)]
17. Schlegel, W., Rotermund, S., Farber, G. and Nieschlag, E. 1981. The influence of prostaglandins on sperm motility. *Prostaglandins* **21**: 87–99. [[Medline](#)]
18. Svanborg, K., Bygdeman, M., Eneroth, P. and Bendvold, E. 1982. Quantification of prostaglandins in human seminal fluid. *Prostaglandins* **24**: 363–375. [[Medline](#)]
19. Templeton, A. A., Cooper, I. and Kelly, R. W. 1978. Prostaglandin concentrations in the semen of fertile men. *J. Reprod. Fertil.* **52**: 147–150. [[Medline](#)] [[CrossRef](#)]
20. Traas, A. M. and Kustritz, M. V. 2004. Effect of administering oxytocin or prostaglandin F2alpha on characteristics of the canine ejaculate. *Can. Vet. J.* **45**: 999–1002. [[Medline](#)]